Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands

Hans M. Westgeest, Malou C. P. Kuppen, Alphonsus J. M. van den Eertwegh, Ronald de Wit, Juleon L. L. M. Coenen, H. P. (Pieter) van den Berg, Niven Mehra, Inge M. van Oort, Laurent M. C. L. Fossion, Mathijs P. Hendriks, Haiko J. Bloemendal, Addy C. M. van de Luijtgaarden, Daan ten Bokkel Huinink, A. C. M. (Fons) van den Bergh, Joan van den Bosch, Marco B. Polee, Nir Weijl, Andre M. Bergman, Carin A. Uyl-de Groot, Winald R. Gerritsen

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)


In the Dutch CAPRI registry, cabazitaxel treatment as the standard of care and in trials was analyzed. Patients treated with cabazitaxel in trials were fitter and showed outcomes comparable to registration trials. Conversely, those treated in daily practice showed features of more aggressive disease and worse outcome. This may be explained by a worse prognosis at cabazitaxel initiation.
Original languageEnglish
Pages (from-to)e946-e956
JournalClinical genitourinary cancer
Issue number5
Publication statusPublished - 1 Oct 2019

Cite this